

To find the category (Medicare Stars, Federal Employee Program®, etc.) this measure applies to, see our [chart of HEDIS® measures](#).

Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)

Let's work together to improve health outcomes. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet details key points of the featured HEDIS measure.

What is the measure?

The measure assesses the percentage of members who were diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease-modifying, anti-rheumatic drug (DMARD).

The measure looks at members age 18 or older during the measurement year who had at least one ambulatory prescription dispensed for a DMARD during the measurement year.

Event (Diagnosis)

To identify an event or diagnosis, the member will have two of the following with different dates of service on or between January 1 and November 30 of the measurement year, as identified through claims:

1. An outpatient visit with any diagnosis of rheumatoid arthritis. Outpatient visit includes provider office, telephone visit and online assessment.
2. A non-acute inpatient discharge with any diagnosis of rheumatoid arthritis. To identify non-acute inpatient discharges:
 - Identify all acute and non-acute inpatient stays
 - Confirm the stay was for non-acute care based on the presence of a non-acute code on the claim
 - Identify the discharge date for the stay

Notes:

Measure compliance requires one claim for DMARD agent or documentation in the medical record with supporting documentation that clearly notes a DMARD was dispensed to the member.

The event can be identified by a provider other than the PCP. If the diagnosis of rheumatoid arthritis is in error, please contact Florida Blue at 305-921-7227 so we can identify the event claim to request a correction.

Exclusions

- A diagnosis of HIV anytime during the member's history through December 31 of the measurement year
- A diagnosis of pregnancy any time during the measurement year
- Members in hospice are excluded from the eligible population

HEDIS Measure: Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis *(continued)*

Supplemental Data Set

Documentation of a prescription in the measurement year that documents the member's name, prescription name, and date dispensed. This can be a picture of the prescription bottle, a pharmacy label, a medication administration record from infusion suite or documentation from a Patient Assistance Program (PAP) that contains this information.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Description	Prescription		
5-Aminosalicylates	Sulfasalazine		
Alkylating agents	Cyclophosphamide		
Aminoquinolines	Hydroxychloroquine		
Anti-Rheumatics	Auranofin		
	Leflunomide		
	Methotrexate		
	Penicillamine		
Immunomodulators	Abatacept	Certolizumab	Infliximab
	Adalimumab	Etanercept	Rituximab
	Anakinra	Golimumab	Tocilizumb
	Sarilumab	Certolizumab pegol	
Immunosuppressive Agents	Azthioprine		
	Cyclosporine		
	Mycophenolate		
Janus Kinase (JAK)	Tofacitinib	Baricitinib	
Tetracyclines	Minocycline		

Content reproduced with permission from HEDIS® 2020, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to any one who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of this publication, including the full measures and specifications, visit ncqa.org/publications.